[Federal Register: September 10, 2007 (Volume 72, Number 174)]
[Notices]
[Page 51652]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10se07-63]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Lecithin-
Cholesterol Acyltransferase (LCAT) To Reduce Accumulation of
Cholesterol
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in
United States Patent Number 6,635,614 titled ``Use of Lecithin-
Cholesterol Acyltransferase (LCAT) to Reduce Accumulation of
Cholesterol,'' referenced at DHHS as E-007-1996/0-US-03, and
corresponding foreign patent application(s) and issued patent(s), to
AlphaCore Pharma, Inc. having a place of business in the state of
Michigan. The field of use may be limited to the following: FDA or
similar foreign body approved cardiovascular and nephropathy
therapeutic. The United States of America is the assignee of the patent
rights in this invention. The territory may be worldwide. This
announcement is the first notice to grant an exclusive license to this
technology.
DATES: Only written comments and/or application for a license, which
are received by the NIH Office of Technology Transfer on or before
November 9, 2007 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Fatima Sayyid, Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301) 435-4521; Facsimile: (301) 402-0220; e-mail:
Fatima.Sayyid@nih.hhs.gov.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty-bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within 60 days from the date of this published Notice,
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 29, 2007.
David R. Sadowski,
Deputy Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E7-17732 Filed 9-7-07; 8:45 am]
BILLING CODE 4140-01-P